Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TVRDVery BearishResearch Analysisnews

High materiality10/10

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Oct 13, 2025, 2:41 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The significant drop in stock price indicates market disappointment. Prior clinical failures led to similar stock downturns.

AI summary

What happened, with direct paths to the underlying reporting

Tvardi's stock fell 84.18% to $6.58 after trial update. Phase 2 REVERT trial did not meet efficacy goals. Discontinuation rates higher for TTI-101 in IPF patients. FVC improvement similar between placebo and treatment arms. Company has $41 million to fund operations through 2026.

Tvardi's stock fell 84.18% to $6.58 after trial update.
Phase 2 REVERT trial did not meet efficacy goals.
Discontinuation rates higher for TTI-101 in IPF patients.
FVC improvement similar between placebo and treatment arms.
Company has $41 million to fund operations through 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside